Skip to content


  • Poster presentation
  • Open Access

PB.26. MRI-guided breast biopsy in Leeds: 12 years' experience

  • 1,
  • 1 and
  • 1
Breast Cancer Research201416 (Suppl 1) :P10

  • Published:


  • Malignant Lesion
  • Conventional Imaging
  • Breast Biopsy
  • Additional Lesion
  • Final Surgery


MRI-guided biopsy allows sampling of lesions occult on conventional imaging to reach a preoperative histological diagnosis and guide patient management.


We performed a retrospective audit of all MRI-guided biopsies performed in Leeds patients over a 12-year study period from the initiation of this service in April 2002. Data collected: indication for MRI; pre-biopsy MRI score; histology from MRI-guided biopsy and final surgery.


There were 46 MR-guided breast biopsies performed (symptomatic n = 26, screening n = 20). Indication for MRI was to assess extent of malignancy (n = 29), an adjunct to triple assessment (n = 11) and a screening investigation in higher risk patients (n = 6). Pre-biopsy MRI score was classified as indeterminate MRI 3 (n = 22), suspicious MRI 4 (n = 20) and malignant MRI 5 (n = 4). In the MRI 3 subgroup, five proved malignant at MR-guided biopsy with a positive predictive value of 23% (5/22). In the MRI 4/5 subgroup, 14 proved malignant at MR-guided biopsy and a further four malignant lesions were identified at diagnostic surgical biopsy, with an overall positive predictive value of 75% (18/24).


MRI-detected lesions are interpreted in clinical context and attributed an MRI score. If the patient has an increased risk of cancer or there already is a cancer present, any additional lesion should be regarded with a higher level of suspicion. MRI 4/5 lesions have a high positive predictive value for malignancy and should proceed to diagnostic surgical biopsy if the initial MR-guided biopsy is inconclusive.

Authors’ Affiliations

Breast Imaging Unit, St James's University Hospital Trust, Leeds, UK


© Rajan et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.